| Date | Title | Description |
| 17.04.2025 | Norgine strengthens rare disease portfolio with acquisition of Theravia | Acquisition of Theravia from Mérieux Equity Partners represents meaningful step forward in Norgine's strategy for sustainable growth, adding a complementary portfolio of rare disease medicines
Transaction further establishes Norgine's posit... |
| 07.02.2025 | Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany | ~ PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to |
| 20.12.2024 | Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales | ~ PEDMARQSI® (anhydrous sodium thiosulfate) is the first and only treatment available within NHS England and Wales for the prevention of cisplatin-induced ototoxicity (hearing loss) in children and young people (1 month-17 years of age) ~
~... |
| 19.12.2024 | Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management | ~ $13 Million Convertible Debt Repayment from Available Cash ~
~ Elimination of Approximately $1.5 Million in Annual Interest Expense and Potential Equity Overhang of Approximately 1.6 Million Shares ~
RESEARCH TRIANGLE PARK, N.C., Dec. 19,... |
| 12.12.2024 | Fennec Pharmaceuticals to Participate in Upcoming Investor Conference | RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in the virtual ... |
| 13.11.2024 | Fennec Pharmaceuticals to Participate in Upcoming Investor Conference | RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in the 15th Ann... |
| 07.11.2024 | Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update | ~ Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~
~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young Adult (AYA) Segment Following Strategic Investments to Drive Awareness of Ototoxicity & Ado... |
| 31.10.2024 | Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024 | RESEARCH TRIANGLE PARK, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2024 ... |
| 28.10.2024 | Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company’s Next Stage of Growth | ~ Pierre S. Sayad, PhD, M.S., Appointed Chief Medical Officer ~
~ Terry Evans Appointed Chief Commercial Officer ~
~ Christiana Cioffi, MBA, Appointed Chief Strategy Officer ~
RESEARCH TRIANGLE PARK, N.C., Oct. 28, 2024 (GLOBE NEWSWIRE) -- ... |
| 28.10.2024 | Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company’s Next Stage of Growth | ~ Pierre S. Sayad, PhD, M.S., Appointed Chief Medical Officer ~
~ Terry Evans Appointed Chief Commercial Officer ~
~ Christiana Cioffi, MBA, Appointed Chief Strategy Officer ~
RESEARCH TRIANGLE PARK, N.C., Oct. 28, 2024 (GLOBE NEWSWIRE) -- ... |
| 05.09.2024 | Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences | RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming in... |
| 05.09.2024 | Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences | RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming in... |
| 13.08.2024 | Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update | ~ Achieved Second Quarter 2024 Total Net Revenues of $7.3 Million ~
~ Appointed Jeffrey S. Hackman as Chief Executive Officer (CEO) and Member of the Board of Directors ~
~ Company Has Approximately $43 Million in Cash, Cash Equivalents, an... |
| 06.08.2024 | Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024 | Company to Also Participate in 2024 Wedbush PacGrow Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical comp... |
| 06.08.2024 | Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024 | RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2024... |
| 05.08.2024 | Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director | ~ Accomplished Industry Leader Brings Extensive Commercialization and Oncology Expertise ~
~ Assumes Leadership Role at Critical Time to Expand Use of PEDMARK®, the First and Only Approved Treatment to Reduce the Risk of Cisplatin-Induced O... |
| 01.07.2024 | Fennec Pharmaceuticals Announces Management Change | RESEARCH TRIANGLE PARK, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that Adrian Haigh has departed from his position as F... |
| 31.01.2023 | Fennec Pharmaceuticals Announces PEDMARK® (sodium thiosulfate injection) Receives Orphan Drug Exclusivity from U.S. FDA | /EIN News/ -- ~ PEDMARK® is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~
~ Orphan Drug Exclusivity Provides... |
| 17.10.2022 | Fennec Pharmaceuticals Announces Commercial Availability of PEDMARK® (sodium thiosulfate injection) in the United States | ~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients ~
~ Fennec HEARS™ Program Offers Comprehensive Patient Services, Including Access to Care Coordinators... |
| 26.09.2022 | Fennec Pharmaceuticals Announces Second Closing of $20 Million Investment from Petrichor | ~ Under the Terms of the Previously Announced Investment Agreement, $5 Million Already Funded Upon Initial Closing, Which Occurred on August 19, 2022, and $20 Million to be Funded Upon FDA Approval of PEDMARK® Which Occurred on September 20... |
| 22.08.2022 | Fennec Pharmaceuticals Closes First $5 Million Investment From Petrichor | ~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of PEDMARKTM ~
~ Fennec Has the Potential to Access an Additional $20 Million Prior to Decemb... |
| 12.08.2022 | Fennec Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Business Update | ~ PEDMARKTM FDA Prescription Drug User Fee Act (PDUFA) Target Action Date
Set for September 23, 2022 ~
~ Commercial Team Built Out In Anticipation of U.S. Launch of PEDMARKTM ~
~ Recently Announced Up to $45 Million in Funding from Petricho... |
| 23.05.2022 | Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences | RESEARCH TRIANGLE PARK, N.C., May 23, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for ... |
| 27.04.2022 | Fennec Pharmaceuticals Announces FDA Acceptance for Filing of New Drug Application Resubmission for PEDMARK™ | RESEARCH TRIANGLE PARK, N.C., , April 27, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for fi... |
| 25.03.2022 | Fennec Pharmaceuticals to Participate in the 2022 Maxim Virtual Growth Conference | RESEARCH TRIANGLE PARK, N.C., March 25, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate) fo... |
| 24.03.2022 | Fennec Pharmaceuticals Resubmits New Drug Application to U.S. Food and Drug Administration for Pedmark™ | RESEARCH TRIANGLE PARK, N.C., March 24, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced the resubmission of its New Drug Application (NDA) to the U.S. Food an... |
| 31.01.2022 | Fennec Pharmaceuticals Announces Management Change | RESEARCH TRIANGLE PARK, N.C., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate) for ... |
| 29.11.2021 | Fennec Pharmaceuticals Expects to Receive Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Lo... | FDA Pre-Approval Inspection Identified Deficiencies with the Facility of the Drug Product Manufacturer, Which Require Resolution Prior to PEDMARK Approval
RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceutical... |
| 29.11.2021 | Fennec Pharmaceuticals Expects to Receive Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Lo... | RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that it expects to receive a Complete Response Letter (CRL) after the PDUFA target action date ... |
| 28.05.2021 | FENNEC PHARMACEUTICALS INC.
Fennec Pharmaceuticals Resubmits New Drug Application to U.S. Food and Drug Administration for PEDMARK™ | RESEARCH TRIANGLE PARK, N.C., May 28, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company, today announced the resubmission of its New Drug Application (NDA) to the U.S. Food and... |
| 30.03.2021 | FENNEC PHARMACEUTICALS INC.
Fennec Announces Fiscal Year 2020 Financial Results and Provides Business Update | ~ Fennec is Working Closely with its Third-Party Drug Product Manufacturer to Finalize the New Drug Application (NDA) Resubmission for PEDMARK™ ~
~ Resubmission of the NDA for PEDMARKTM is Planned for the Second Quarter of 2021 ~
~ Company ... |
| 30.03.2021 | FENNEC PHARMACEUTICALS INC.
Fennec Pharmaceuticals : Corporate Presentation March 2021 | March 2021 | Corporate Presentation
www.fennecpharma.com
Safe Harbor Statement
During the course of this presentation, we will make statements that constitute forward-looking statements. These statements may include operating expense projec... |
| 30.03.2021 | Fennec Pharmaceuticals : Corporate Presentation March 2021 | March 2021 | Corporate Presentation
www.fennecpharma.com
Safe Harbor Statement
During the course of this presentation, we will make statements that constitute forward-looking statements. These statements may include operating expense projec... |
| 12.08.2020 | FENNEC PHARMACEUTICALS INC.
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences | RESEARCH TRIANGLE PARK, N.C., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that Rosty Raykov, Chief Executive Officer of Fennec will present at the following upcoming inv... |
| 09.06.2017 | Fennec Pharmaceuticals Raises $7.6M | Biotech company Fennec Pharmaceuticals Inc. has raised $7.6 million in a private equity offering, according to a filing Thursday with the Securities and Exchange Commission.
The money came from seven investors who purchased 1.9 million shar... |
